Discussion about this post

User's avatar
Gavin Giovannoni's avatar

Good news. Just received the following response from Merck MENA (middle East and North Africa):

Availability: Palestinian MOH has received Rebif 44 mcg supply in 2022 to cover their estimated demand for West Bank and Gaza Strip for the year.

Process: The Palestinian MOH has an official process for dispensing medications, where patients must be enrolled in the MOH list of patients to receive their respective medication. To be enrolled, all patients must complete and submit an application to the MOH, and accordingly, the MOH can dispense the medication to them on monthly basis, free of charge.

Support: Due to the security situation in Gaza Strip, Merck does not have a PSP/PAP there, however, we do have in West Bank. Merck’s PSP nurse in West Bank would gladly support this patient in completing the application and guiding here through the above mentioned process (Merck PSP/mobile number ***).

Expand full comment
Stephen Warne's avatar

To be blunt with what seems to be some sort of postcode lottery regarding MS treatment in the UK its not so different here I’m afraid. My wife two years after initial diagnosis- no neurologist follow up, no determination of type of MS, no ‘frequent’ scans (had to ask for one after two tears of in action - still waiting 8 weeks later to even get an appointment letter let alone an appointment). So no determination of type of MS and if appropriate DMT/antiviral treatment.

Meanwhile her disability is getting worse.

Tbat doesn’t mean I haven’t got huge compassion for people in a similar situation in lower income countries and they deserve treatment and answer just as much but things need to change here too. The feeling of despair of disability increasing in the face of inaction knows no borders.

Expand full comment
15 more comments...

No posts